Partial
Partially Aligned
Patient Risk:
Info
Summary
Many claims about hepatotoxicity/pregnancy risk are not evaluated here because the provided label excerpts focus on hepatotoxicity monitoring/REMS and embryo-fetal toxicity (pregnancy contraindication). Claims about abrupt discontinuation and clinical worsening are not supported by the provided label text.
Category Scores
Accurate Statements
Clinicians may advise discontinuation for safety concerns such as serious liver toxicity.
Supported by labeled hepatotoxicity warning/criteria (Section 5.1 and Section 2.4: discontinue for symptomatic hepatotoxicity; Boxed Warning referenced).
When prompt discontinuation is required, clinicians balance the urgency of stopping against the risk of PAH worsening.
Partially supported only in concept that discontinuation may be required due to hepatotoxicity (Section 2.4/5.1), but the specific balancing language is not present in the provided excerpt.
When prompt discontinuation is required, clinicians may implement close monitoring and/or alternative therapy.
Partially supported by requirement for close monitoring of liver aminotransferases/bilirubin (Section 2.1, 5.2), but alternative-therapy language is not present in the provided excerpt.
Unsupported Statements
Abruptly discontinuing bosentan can worsen pulmonary arterial hypertension (PAH) symptoms in some patients.
No provided label text supports that abrupt withdrawal worsens PAH symptoms.
Bosentan is an ongoing therapy that helps control PAH.
No provided label text in the excerpts states that bosentan must be continued or that abrupt discontinuation worsens outcomes; indications for ongoing use are not explicitly described in the provided excerpt.
Sudden stopping of bosentan may lead to clinical deterioration such as worsening shortness of breath.
No provided label text supports symptom worsening with abrupt discontinuation.
Sudden stopping of bosentan may lead to clinical deterioration such as worsening fatigue.
No provided label text supports fatigue worsening with abrupt discontinuation.
Sudden bosentan discontinuation may cause a return or increase in common PAH symptoms.
No provided label text supports return/increase of PAH symptoms after discontinuation.
After abrupt bosentan withdrawal, shortness of breath (especially with exertion) may worsen.
No provided label text supports this.
After abrupt bosentan withdrawal, reduced exercise tolerance may occur.
No provided label text supports this.
After abrupt bosentan withdrawal, new or worsening fatigue may occur.
No provided label text supports this.
After abrupt bosentan withdrawal, swelling from fluid retention (edema) may worsen.
No provided label text supports this.
After abrupt bosentan withdrawal, overall functional status may worsen.
No provided label text supports this.
Bosentan is typically continued long-term.
No provided label text states typical long-term continuation.
Discontinuation of bosentan is usually handled in a controlled way.
No provided label text describes discontinuation strategy as 'controlled way' for PAH worsening.
If bosentan must be stopped, clinicians generally plan an alternative approach rather than stopping it 'cold turkey.'
No provided label text supports this specific discontinuation management concept.
Bosentan helps lower pulmonary vascular resistance by blocking endothelin receptors.
No provided label text in the excerpts states the mechanism 'blocking endothelin receptors' or that it lowers PVR via that mechanism.
Stopping bosentan removes its pharmacologic effect.
No provided label text supports this general pharmacologic-effect statement.
After stopping bosentan, pulmonary pressures can rise again.
No provided label text supports pulmonary pressure rise after stopping.
Pulmonary pressure rise after stopping bosentan can lead to symptom worsening in susceptible patients.
No provided label text supports this.
Patients should not stop bosentan abruptly on their own.
No provided label text contains an instruction specifically advising patients not to stop abruptly.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
The provided label excerpts emphasize pregnancy contraindication and reproductive precautions (exclude pregnancy prior to initiation; use effective contraception during treatment and for at least 1 month after last dose; discontinue as soon as possible if pregnancy occurs), but the claim set provided in the prompt is not primarily about these label-specific pregnancy management details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Unsupplied label support for multiple abrupt-discontinuation worsening claims creates potential for misinformation; however, no contraindication- or dosing-specific unsafe guidance was directly contradicted by the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims about abrupt bosentan withdrawal worsening PAH symptoms (e.g., shortness of breath, fatigue, edema, exercise tolerance, functional status, pulmonary pressure rise) are not supported by the provided FDA PI excerpts.
Suggested Improvement
Limit statements to what is supported: hepatotoxicity monitoring and discontinuation criteria (ALT/AST and bilirubin thresholds; discontinue if symptomatic hepatotoxicity or bilirubin ≥2× ULN; REMS/monthly monitoring) and embryo-fetal toxicity/pregnancy contraindication and reproductive precautions (exclude pregnancy before initiation; effective contraception; discontinue as soon as possible if pregnancy occurs). Remove or qualify the abrupt-withdrawal symptom worsening claims unless additional label text is provided.